In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
2-Benzylbenzimidazole ‘nitazene’ opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, we assessed in vitro structure–activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, we focused on MOR activation by ‘ring’ substituted analogues (i.e., N -pyrrolidino and N -piperidinyl modifications), ‘desnitazene’ analogues (lacking the 5-nitro group), and N -desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that ‘ring’ modifications overall yield highly active drugs. With the exception of 4′-OH analogues (which are metabolites), N -pyrrolidino substitutions were generally more favorable for MOR activation than N -piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N -desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N -desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, we describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N -desethyl etonitazene, N -desethyl isotonitazene, N -pyrrolidino metonitazene, and N -pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs’ high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of a nitazene analogue even at trace amounts, which could be below the cut-off for detection with NTS, may readily give rise to dangerous opioid effects in (unknowing) users.”
From Nitazene test strips: a laboratory evaluation (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we found e.g. etodesnitazene to have a similar in vitro potency and efficacy as fentanyl [7, 13]”
From Nitazene test strips: a laboratory evaluation (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent emergence of ultrapotent nitazenes, the N‐pyrrolidino analogues, has amplified public health concern because their potency have been reported to be up to 45 times that of fentanyl [7].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They are μ opioid receptor agonists with potency that ranges from that comparable to fentanyl (e.g. metonitazene), to 45‐fold greater (N‐desethyl isotonitazene), based on in vitro μ‐opioid receptor activity assays [7].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“N‐Pyrrolidino etonitazene (etonitazepyne) differs structurally from other nitazenes [28] in a way that makes etonitazepyne approximately 40 times more potent than fentanyl [7], with greater activation of the β‐arrestin2 pathway (EC50 = 0.548 nM).”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336 · cited 1×
“Therefore, the proposed in vitro SAR trends, indicating a (very) high MOR activating potential of many of the investigated compounds, may be cautiously extrapolated to the in vivo setting (Gillis et al. 2020; Tsai et al. 2024).”
BackgroundFriedman, J., & Shover, C. L. (2023) · Addiction · doi:10.1111/add.16318 · Cited by 322
Zhang, R., & Xie, X. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.173 · Cited by 317 · cited 1×
“…levels (upstream and further downstream) in a common cellular background (HEK 293T cells) can be considered a strength of this study, it is important to consider some inherent differences in the characteristics of the assays that were deployed (Zhang and Xie 2012; Vandeputte et al. 2022d).”
BackgroundVandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Self-citationThe atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
Meyrath, M., Szpakowska, M., Zeiner, J., Massotte, L., Merz, M. P., Benkel, T., Simon, K., Ohnmacht, J., Turner, J. D., Krüger, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16664-0 · Cited by 152 · cited 1×
“The pNBe2 expression vector encoding the human MOR, C-ter-minally tagged with SmBiT (part of the NanoBiT ® system), was kindly provided by Dr. Andy Chevigné and was previously reported by Meyrath et al. (2020).”
MethodCharbogne, P., Kieffer, B. L., & Befort, K. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.028 · Cited by 147 · cited 1×
“MOR is the main molecular target for most therapeutic and abused opioids (Charbogne et al. 2014).”
BackgroundIsotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146 · cited 7×
“N -Desethyl etonitazene and N -desethyl isotonitazene are metabolites of etonitazene and isotonitazene, respectively (Taoussi et al. 2024; Kanamori et al. 2024; Krotulski et al. 2020).”
BackgroundMethodInfluentialSelf-citationDARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141 · cited 14×
“This allowed us to further build on known SAR trends within the nitazene class, focusing on the structural modifications observed in nitazenes that have recently emerged on the NPS markets in the U.S. and around the world.”
BackgroundInfluentialLaing, M. K., Ti, L., Marmel, A., Tobias, S., Shapiro, A. M., Laing, R., Lysyshyn, M., & Socías, M. E. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103169 · Cited by 124 · cited 11×
“This allowed us to further build on known SAR trends within the nitazene class, focusing on the structural modifications observed in nitazenes that have recently emerged on the NPS markets in the U.S. and around the world.”
BackgroundInfluentialBlanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116 · cited 1×
“Apart from occasional identifications of etonitazene between 1966 and 2003 (Brandenberger 1974; Sorokin 1999; Sorokin et al. 1999; Reavy 2003; Morris 2009), it was not until 2019 that the first nitazene was identified on the recreational drug market (Blanckaert et al. 2020; Vandeputte et al. 2021).”
BackgroundSelf-citation
Research works printed but not linked: 7
- Brandenberger H (1974) Rolle des massenspektrometers im toxikologisch-chemischen laboratorium. Dtsch Lebensm-Rundsch 70:31–39
- EMCDDA (2020) Report on the risk assessment of N,N-diethyl-2-[[4-(1-methylethoxy) phenyl] methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). Publications Office, Luxembourg
- EMCDDA (2023) European drug report 2023: trends and developments. Publications Office of the European Union, Luxembourg
- Krotulski A, Papsun D, Walton SE, Logan BK (2022) Benzo-dope: an increasingly prevalent drug combination of significant toxicological relevance. Society of forensic toxicologist (SOFT)- 2022 conference meeting
- Sorokin VI (1999) Illegal synthesis of etonitazene. J Clan Lab Invest Chem Assoc 9:20
- Sorokin VI, Ponkratov KV, Drozdov MA (1999) Etonitazene encountered in Moscow. Microgram 32:239
- UNODC (2020) The growing complexity of the opioid crisis. Global SMART update (2020) vol 24. Austria, Vienna
Cited by
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Self-citationVandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107503 · Cited by 35
Self-citationNitazene test strips: a laboratory evaluation
De Vrieze, L. M., Stove, C. P., & Vandeputte, M. M. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01078-8 · Cited by 34
“Nitazene opioids generally display high levels of opioid activity, with potencies and efficacies often exceeding that of fentanyl [7, 12, 13].”
BackgroundInfluentialSelf-citationNitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Bade, R., Nadarajan, D., Hall, W., Brown, J. A., NPS Wastewater Consortium, & Schumann, J. (2025) · Addiction · doi:10.1111/add.70027 · Cited by 28
Metadata
- Authors
- De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M.
- Affiliations
- Fredric Rieders Family Foundation (US)
- Ghent University (BE)
- Corresponding author
- Stove, Christophe P.
- Vandeputte, Marthe M.
- ORCID
- Venue
- Archives of Toxicology
- Published
- 2024-06-14
- Volume
- 98
- Issue
- 9
- Pages
- 2999-3018
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC11324687
- OpenAlex
- W4399665315
- Cited by
- 58
- References
- 53
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 5
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- Funders
- Office of Justice Programs (15PNIJ-22-GG-04434-MUMU)
- Fonds Wetenschappelijk Onderzoek (11I5623N, 1S81522N, G069419N)
- Bijzonder Onderzoeksfonds UGent (BOF23/PDO/073, 01J15517)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- structure-activity relationship, mu-opioid receptor, etonitazene, isotonitazene, opioid potency, forensic toxicology
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Humans, Nitro Compounds, Structure-Activity Relationship, Receptors, Opioid, mu, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids. https://app.cochat.ai/papers/10.1007/s00204-024-03774-7
- The paper
- De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024). In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03774-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.